Patients
lung cancer, metabolic diseases, Cancer
IMMUNE SYSTEM DISEASES, LUNG CANCER, SMALL CELL LUNG CANCER, METABOLIC DISEASES, ONCOLOGY, CANCER
This study intended to screen and enroll chemotherapy‐naive patients with lung cancer who were scheduled to receive platinum‐based doublet chemotherapy. The quality of life score of lung cancer patients during chemotherapy was around 60 (Figure The flow chart of patient disposition.Patients who met all of the following criteria were included: (1) pathologically confirmed with lung cancer (including non‐small cell lung cancer and small cell lung cancer); (2) chemotherapy‐naive; (3) aged between 18 and 75 years old; (4) Eastern Cooperative Oncology Group performance status (ECOG PS) 0–2; (5) receiving chemotherapy for the first time with a regimen of cisplatin/carboplatin (AUC ≥5) in combination with one of these following agents: paclitaxel, docetaxel, gemcitabine, vinorebine, pemetrexed, etoposide, and who were supposed to receive two or more cycles of chemotherapy.The main exclusion criteria were as follows: (1) Patients who received recent (within 2 weeks before chemotherapy) antibiotic therapy or proton pump inhibitor therapy, (2) patients who had recently (within 2 weeks before chemotherapy) taken some probiotic preparations, (3) patients with chronic gastrointestinal diseases or gastrointestinal metastatic tumor, (4) patients with severe systemic metabolic diseases or immune system diseases.Based on the computer‐generated program, enrolled patients were randomly assigned (1:1) to either the compound probiotic supplements group (group BP‐1) or the placebo group (group C). A total of 110 random identification numbers were created by the computer before patients enrolled. Each enrolled patient was given an identification number based on the enrolment order and assigned to the corresponding group based on the identification number. The process mentioned above was performed by the Cancer Psychology and Health Management Committee of the Sichuan Cancer Society and was double‐blind for both subjects and researchers.